http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Kim, Chul Soo,Kim, Dong Soon,Kim, Re Hwe 인제대학교 1991 仁濟醫學 Vol.12 No.1
1983년 3월부터 1987년 11월까지 20명의 제4기 비소세포폐암환자에게 Cisplatin, Ifosfamide, Bischlorethyl Nitrosurea로써 치료를 시도하였다. 복합 항암화학요법으로서 Bischlorethyl Nitrosurea는 제1일에 체표평방m당 60mg을 정주로, Cisplatin은 제2일에 체표평방m당 60mg을 정주로 Ifosfamide는 제 3,4,5,6,7일에 체표평방m당 1.2g을 매일 정주로 투입하였고 상기치료는 매5주 또는 6주 간격으로 반복하였다. 환자에게 투여된 치료의 횟수는 그 중앙치가 3회였으며 20명중 5명은 추적이 불가능하여 15명에서만 판정이 가능하였다. 15명중 4명(27%)에서 부분관해가 이루어졌고 2명(13%)에서는 종괴의 성장이 일시적으로 정지되었고 9명은 치료에 반응하지 않았다. 반응군의 관해지속기간은 그 중앙치가 6개월(범위 4개월-10개월)이었고 생존기간은 그 중앙치가 10개월(범위 7개월-20개월)이었으며 비반응군의 생존기간은 중앙치가 2개월(범위 1개월-12개월)이었다. 본제제의 독성은 상당하여 3명(20%)이 치료기간 도중 사망하였고 8명(53%)에서 심한 위장관장해가 있었다. 기타 부작용으로서 2례(13%)의 방광염 증세, 1례(7%)의 신독성, 1례(7%)의 청각장애, 2례(13%)의 완전탈모가 있었으며 3례의 발열이 관찰되었으나 이중 1례(7%)만이 백혈구 감소와 동반되었다. 골수는 차기 화학요법 전에 1례만을 제외하고는 모두 정상으로 회복되었다. 치료효과와 독성을 견주어 볼때 상기제제는 말기의 비소세포암 환자의 표준치료법으로서 권장될 수 없으며 그 사용에 있어 환자의 선별에 매우 세심한 주의를 요할것으로 사료된다. Cisplatin (60mg/sq m), ifosfamide (6g/sq m in 5 fractional doses) and bischorethyl nitrosourea (60mg/sq m) were given every five or six weeks to twenty disseminated non small cell lung cancer patients. The median treatment courses were three. Among fifteen evaluable patients, four (27%) responded partially and two (13%) showed temporary arrest of disease progression. The median survival duration of responders was 46 weeks (range 30-86 weeks) and corresponding duration of non responders was 9 weeks (range 5-52 weeks). Toxicities of the regimen were severe three patients (20%) died during the treatment and eight patients (53%) had considerable gastrointestinal symptoms. Other side effects included two cases (13%) of overt cystitis, one case (7%) of nephrotoxicity, one case (7%) of hearing loss, and two cases (13%) of total alopecia. There were three febrile episodes, one of which (7%) was associated with leukopenia. Bone marrow returned to normal in all patients except one (7%) before subsequent chemotherapy. The regimen seemed not to be better than other cisplatin based regimens in therapeutic gains and toxicities. It is recommended the regimen be resealed only for highly selected group of patients.
일반 Aminophylline 과 Theophylline 서방정 Ascontin(R) 및 Uniphyl(R) 제제의 혈중 농도변화에 관한 연구
김동순,김성삼,최수전,김면호,유원상,김예희 대한내과학회 1986 대한내과학회지 Vol.30 No.1
Serial change in serum aminophylline level was observed in 22 patients with chronic obstructive pulmonary disease after the administration of aminophylline tablet (6 patients), Ascontin(R) (12 hour slow releasing tablet; 8 patients), and Uniphyl(R) (24 hour slow releasing tablet; 8 patients). The peak serum level was reached in 1 hour after the administration of aminophylline, 4 hour in Ascontin(R) group and 6~9 hours in Uniphyl(R) group. The effective serum level was maintained for 5.5 hours in aminophylline group, 11 hours in Ascontin(R) group, and 18 hours in Uniphyl(R) group. The peak serum level, the difference between the peak and trough level, AUC(area under the curve), mean serum level and g$gt; fluctuation were not significantly different between each groups. But the side effect was much less in slow releasing tablet groups. 2 patients could not continue to take aminophylline tablet due to severe gastrointestinal symptoms and another 2 patients also complained of indigestion and nausea. Transient gastrointestinal discomfort was observed in 2 patients in Uniphyl(R) group but no side effect was seen in Ascontin(R) group.
Kim, Chul Soo,Kim, Sung Rok,Suh, Hyun Suk,Kim, Dong Soon,Kim, Nam Won,Noh, Seong Hyun,Ko, Won Sub,Ahn, Jung Hyo,Lee, Yong Suk,Choi, Soo Jeon,Kim, Re Hwe 인제대학교 1990 仁濟醫學 Vol.11 No.1
조직 학적으로 확진된 32명의 소세포 폐암환자를 약용량 복합항암화학요법 (CAV-cyclophosphamide, adriamycin. vincristine 또는 PVP16-cisplatinum, etoposide 또는 CAV-PVP16교대요법)및 전용량 방사선요법(45-50Gy)으로 치료한 결과, 판정이 가능한 27명 중 23명이 반응하여 85%의 반응률을 얻었다. 이를 병기별로 보았을 때 국소병기에 속하였던 16명 중 6명에서 완전 관해(37%), 9명에서 부분 관해(57%)를 보였고, 이들의 생존기간의 중앙치는 13개월이었으며, 진전병기에 속하였던 11명 중 8명이 반응(73%)하였으나 완전 관해는 한명도 없었고, 이들의 생존기간의 중앙치는 5개월이었다. 국소병기에 속하였던 한명은 현재 69개월간 재발 없이 생존하여 완치로 간주되었고, 다른 한명은 17개월간 재발 없이 생존하고 있다. 치료로 야기된 부작용은 경미하였다. 약용량 복합항암화학요법은 진전병기의 소세포 폐암의 치료에 있어서는 용량이 미흡하였으나 국소병기의 소세포 폐암의 경우에는 방사선요법과 동반되었을 때 강용량의 복합항암화학요법의 치료 결과와 비견할만 하였다. Thirty two small cell lung cancer patients received attenuated CAV (vincristine, adriamycin and cyclophosphamide) or PVP16 (cia-platinum and etoposide) or CAV-PVP16 alternating combination chemotherapy with or without chest irradiation. 23 of 27 evaluable patients responded to give an overall response rate of 85%. Among 16 patients in limited stage, 6 entered complete remission (37%) and 9 showed partial remission (57%). 8 of 11 patients in extensive stage responded (73%) with no complete remission. Corresponding median survivals were 13 and 5 months. One patient was cured. Treatment related toxicity was minimal. The attenuated combination chemotherapy seemed suboptimat in reduction of bulky tumor but comparable to aggressive combination chemotherapy in dealing with small burden of tumor when combined with radiation.
김유래 ( Yu Re Kim ),김만기 ( Man Gi Kim ),경규상 ( Kyu Sang Kyeong ),조아라 ( A Ra Jo ),홍승화 ( Seung Hwa Hong ),박연진 ( Yeon Jin Park ),지일운 ( Ill Woon Ji ),정은환 ( Eun Hwan Jeong ),김학순 ( Hak Soon Kim ),이옥준 ( Ok Jun L 대한산부인과학회 2006 Obstetrics & Gynecology Science Vol.49 No.9
Large cell neuroendocrine carcinoma of the uterine cervix is a rare and highly aggressive cervical neoplasm. Metastases and recurrences of the tumor are common. Cervical large cell neuroendocrine carcinomas are distinctive cervical carcinomas that are frequently misdiagnosed and have unfavorable prognosis. So prudential care must be considered for proper diagnosis and multimodal treatment may be required for better survival. We experienced one case of large cell neuroendocrine carcinoma accompanied with adenocarcinoma of the uterine cervix in 52 year old woman. The uterine cervix covered and infiltrated with adenocarcinoma cells and attached polypoid mass (3.2×2.1 ㎝) composed of large cell neuroendocrine carcinoma cells. The diagnosis was confirmed by immuno-staining using cytokeratin (+), synaptophysin (+), chromogranin (+), neuron-specific enolase (+), CD 56 (+), and vimentin (-). So we report the case with brief review of the literature.
Bak, Dong Ho,Choi, Mi Ji,Kim, Soon Re,Lee, Byung Chul,Kim, Jae Min,Jeon, Eun Su,Oh, Wonil,Lim, Ee Seok,Park, Byung Cheol,Kim, Moo Joong,Na, Jungtae,Kim, Beom Joon The Korean Society of Pharmacology 2018 The Korean Journal of Physiology & Pharmacology Vol.22 No.5
Human umbilical cord blood mesenchymal stem cells (hUCB-MSCs) are used in tissue repair and regeneration; however, the mechanisms involved are not well understood. We investigated the hair growth-promoting effects of hUCB-MSCs treatment to determine whether hUCB-MSCs enhance the promotion of hair growth. Furthermore, we attempted to identify the factors responsible for hair growth. The effects of hUCB-MSCs on hair growth were investigated in vivo, and hUCB-MSCs advanced anagen onset and hair follicle neogeneration. We found that hUCB-MSCs co-culture increased the viability and up-regulated hair induction-related proteins of human dermal papilla cells (hDPCs) in vitro. A growth factor antibody array revealed that secretory factors from hUCB-MSCs are related to hair growth. Insulin-like growth factor binding protein-1 (IGFBP-1) and vascular endothelial growth factor (VEGF) were increased in co-culture medium. Finally, we found that IGFBP-1, through the co-localization of an IGF-1 and IGFBP-1, had positive effects on cell viability; VEGF secretion; expression of alkaline phosphatase (ALP), CD133, and ${\beta}-catenin$; and formation of hDPCs 3D spheroids. Taken together, these data suggest that hUCB-MSCs promote hair growth via a paracrine mechanism.
Dong Ho Bak,Mi Ji Choi,Soon Re Kim,Byung Chul Lee,Jae Min Kim,Eun Su Jeon,Wonil Oh,Ee Seok Lim,Byung Cheol Park,Moo Joong Kim,Jungtae Na,Beom Joon Kim 대한약리학회 2018 The Korean Journal of Physiology & Pharmacology Vol.22 No.5
Human umbilical cord blood mesenchymal stem cells (hUCB-MSCs) are used in tissue repair and regeneration; however, the mechanisms involved are not well understood. We investigated the hair growth-promoting effects of hUCB-MSCs treatment to determine whether hUCB-MSCs enhance the promotion of hair growth. Furthermore, we attempted to identify the factors responsible for hair growth. The effects of hUCB-MSCs on hair growth were investigated in vivo, and hUCB-MSCs advanced anagen onset and hair follicle neogeneration. We found that hUCB-MSCs coculture increased the viability and up-regulated hair induction-related proteins of human dermal papilla cells (hDPCs) in vitro. A growth factor antibody array revealed that secretory factors from hUCB-MSCs are related to hair growth. Insulin-like growth factor binding protein-1 (IGFBP-1) and vascular endothelial growth factor (VEGF) were increased in co-culture medium. Finally, we found that IGFBP-1, through the colocalization of an IGF-1 and IGFBP-1, had positive effects on cell viability; VEGF secretion; expression of alkaline phosphatase (ALP), CD133, and β-catenin; and formation of hDPCs 3D spheroids. Taken together, these data suggest that hUCB-MSCs promote hair growth via a paracrine mechanism.